32361326 2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.
| 32504046 2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
| 32092539 2020. Is COVID-19 receiving ADE from other coronaviruses?
32268188 ä. It is too soon to attribute ADE to COVID-19
antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.
| 31826992 2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
| 32317716 ä. The potential danger of suboptimal antibody responses in COVID-19
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32303697 ä. Will we see protection or reinfection in COVID-19?
32438257 2020. SARS-CoV-2 and enhancing antibodies
the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...
| 32408068 2020. What about the original antigenic sin of the humans versus SARS-CoV-2?
32436320 2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.
32506725 2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
32529906 2020. Serological differentiation between COVID-19 and SARS infections.
32380903 2020. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.
32426212 2020. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
32526272 2020. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.
32590062 2020. lall? Due diligence warranted for ADE in COVID-19.
| 32595955 2020. Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population.
32582200 2020. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.